Drug companies contributed to the opioid crisis, but so did lots of other stakeholders, says Glenn W. Simon in National Review. » Read More
By: Dan Mangan
Martin Shkreli's bail was revoked last week by a judge for having offered Facebook followers $5,000 for samples of Hillary Clinton's hair. » Read More
By: Tae Kim
Goldman Sachs lowers its rating for Johnson & Johnson to sell from neutral. » Read More
Lior Dayan, CEO of Sisram Medical, says choosing Hong Kong was a natural choice for the company given its presence in China and explains how IPO funds will be used. » Read More
Steven Richardson has said he told Shkreli to stop making homoerotic remarks around him.
Jurors could begin deliberating Shkreli's fate on Friday.
Martin Shkreli is accused of looting his drug company to pay off defrauded investors in his hedge funds.
A combination of durva/treme failed to beat chemotherapy.
Traditionally patients have been told they must finish a prescribed course of antibiotics.
Closing arguments are expected to stretch into Friday morning in the case of the notorious "Pharma bro."
AstraZeneca shares fell 15 percent after disappointing results for a lung cancer treatment in highly anticipated clinical trial.
The drug maker's combination of two injectable immunotherapy drugs failed to help patients as hoped.
CNBC's Meg Tirrell reports shares of the pharmaceutical giant are having a bad day after the company's experimental lung cancer drug failed to pass a major test.
CNBC's Carolin Roth reports from Basel, Switzerland, on pharmaceutical firm Roche's second quarter earnings with comment from CEO Severin Schwan.
Mick Cooper, analyst Trinity Delta, discusses pharma giant AstraZeneca following news that an immunotherapy drug it was trialing has been less successful than was hoped.
Roche raised its 2007 outlook, just as the Swiss group's ageing portfolio of blockbuster medicines faces increasing competition.
Jurors could begin their deliberations exactly one month after hearing opening arguments in the securities fraud case.
Biotech Amgen's second-quarter earnings report revealed the company's growth is slowing and a buildup in inventories.
"You can't omit important pieces of a story and expect the people will be too stupid to figure it out," Shkreli wrote Monday.
Jurors could begin deliberating Shkreli's fate on Thursday.
Eli Lilly CEO David Ricks said on an earnings call Tuesday that he hopes a policy includes some of the reforms the industry has pushed for.
"I am really starting to think you are inept," Martin Shkreli fumed in an email to attorney Evan Greebel.
Prosecutors could conclude their case as early as Tuesday, and it is not clear if Shkreli's lawyers will present any witnesses.
CNBC's Meg Tirrell reports on the Democrats' "better plan" on prescription price gouging. The “Fast Money Halftime Report” traders weigh in.
Get the best of CNBC in your inbox